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ABSTRACT
Although historically the intra-aortic balloon pump has been the only mechanical circulatory support device available to
clinicians, a number of new devices have become commercially available and have entered clinical practice. These include
axial ﬂow pumps, such as Impella; left atrial to femoral artery bypass pumps, speciﬁcally the TandemHeart; and new devices
for institution of extracorporeal membrane oxygenation. These devices differ signiﬁcantly in their hemodynamic effects,
insertion, monitoring, and clinical applicability. This document reviews the physiologic impact on the circulation of these
devices and their use in speciﬁc clinical situations. These situations include patients undergoing high-risk percutaneous
coronary intervention, those presenting with cardiogenic shock, and acute decompensated heart failure. Specialized uses
for right-sided support and in pediatric populations are discussed and the clinical utility of mechanical circulatory support
devices is reviewed, as are the American College of Cardiology/American Heart Association clinical practice guidelines.
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INTRODUCTION

shock syndrome, 2) reduce intracardiac ﬁlling pressures,
thereby reducing congestion and/or pulmonary edema,

Percutaneous hemodynamic support has historically

3) reduce left ventricular volumes, wall stress, and

been limited to the intra-aortic balloon pump (IABP)

myocardial oxygen consumption, 4) augment coronary

or extracorporeal bypass with membrane oxygenator

perfusion, 5) support the circulation during complex inter-

(ECMO) (1–3). Although the IABP is widely available,

ventional and electrophysiologic procedures, and, theo-

limitations include modest hemodynamic support or

retically, 6) limit infarct size. As new MCS devices become

myocardial protection; ECMO can provide full hemody-

available, several speciﬁc patient populations likely to

namic support but is limited by complexity and need for

beneﬁt from this therapy can be identiﬁed. These include

perfusion expertise and is rarely used in the catheteri-

patients undergoing high-risk PCI (HR-PCI), and those

zation laboratory environment. These limitations have

with large acute myocardial infarctions (AMI), acute de-

spurred development of alternative percutaneous me-

compensated heart failure (ADHF), and cardiogenic shock.

chanical circulatory support (MCS) devices with the po-

The hemodynamic condition of the left ventricle (LV)

tential to provide greater cardiac and systemic support

in these populations is illustrated by the pressure-volume

and reduce morbidity and mortality among high-risk

(PV) loop (Figure 1), which provides information about

patient subsets (1).

contractile function, relaxation properties, stroke vol-

In parallel, cardiovascular practice has seen rapid

ume, cardiac work, and myocardial oxygen consumption

growth in cohorts that may beneﬁt from the use of such

(6–10). The anticipated effect with available support de-

devices (4). These include patients with chronic systolic

vices is shown in Figure 2. Each clinical syndrome pre-

dysfunction and acute decompensated heart failure

sents a unique set of hemodynamic variables where

(ADHF), those in whom high-risk multivessel percuta-

cardiac function and myocardial oxygen supply or de-

neous coronary intervention (PCI) or other procedures

mand is compromised. For example, in AMI, patients may

may be required, those with acute cardiogenic shock, and

present with reduced LV contractile function, acute dia-

those with residual or concomitant cardiac dysfunction

stolic dysfunction, elevated LV end-diastolic volume

from myocardial infarction despite reperfusion. Among

(LVEDV) and pressure (LVEDP), and increased LV work

patients with cardiogenic shock, in particular, acute im-

(oxygen demand) in addition to diminished coronary

plantation of surgical MCS remains associated with rela-

blood ﬂow. In cardiogenic shock LV contractile function is

tively poor outcomes. Accordingly, there has been a

severely reduced with signiﬁcantly increased LVEDV and

rise in the development and use of percutaneous devices

LVEDP, markedly reduced stroke volume, but increased

over the past decade for both acute (e.g., acute myo-

myocardial oxygen demand; coronary blood ﬂow may also

cardial infarction (MI) complicated by cardiogenic shock

be impaired by hypotension and elevated wall stress.

or mechanical complications) and acute on chronic

These pressure-volume loops provide hemodynamic

(e.g., high risk (HR) PCI) indications.

characterization only of the LV and do not provide in-

Percutaneous MCS devices have become an integral

formation on right ventricular function or extra-cardiac

component of the cardiovascular therapeutic armamen-

problems that may be impacted by MCS such as sys-

tarium. The 2011 American College of Cardiology/American

temic hypoperfusion of the cerebral, visceral, renal, and

Heart Association/Society for Cardiovascular Angiog-

peripheral arteries.

raphy

and

Interventions

(ACC/AHA/SCAI)

Guideline

for Percutaneous Coronary Intervention recommends

HR PCI

consideration of percutaneous MCS in two clinical settings:
a) as an adjunct to HR PCI (Class IIb) and b) for cardiogenic

Each aspect of PCI from guide catheter engagement to

shock in patients presenting with ST-elevation myocardial

coronary wiring, balloon inﬂation, and stent deployment

infarction (Class Ib) (5). However, no additional guidance

incurs a potential risk of damage to the coronary vascu-

is provided. The goal of this document is to provide such

lature with impairment of myocardial perfusion, either

guidance on the appropriate clinical settings for MCS

transient or persistent. At present, no single, unifying

utilization and to review the available devices, treatment

deﬁnition for HR-PCI exists but variables that contribute

strategies, practical recommendations for use, gaps in

to elevated risk during PCI have been well deﬁned and

knowledge, and evolving practice.

can be categorized into three major groups: 1) patient

CLINICAL SETTINGS AND

speciﬁc.

speciﬁc, 2) lesion speciﬁc, and 3) clinical presentation

HEMODYNAMIC SUBSTRATES

Patient-speciﬁc variables include increased age, impaired left ventricular function, symptoms of heart fail-

Potential beneﬁts of MCS include the ability to: 1) main-

ure, diabetes mellitus, chronic kidney disease, prior

tain vital organ perfusion, thereby preventing systemic

myocardial infarction, multivessel or left main disease,
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F I G U R E 1 Normal and Abnormal Pressure Volume Loops

Each pressure volume (PV) loop represents one cardiac cycle (A). Beginning at the end of isovolumic relaxation (Point 1), LV volume increases during diastole
(Phase 1 to 2). At end-diastole (Point 2), LV volume is maximal and isovolumic contraction (Phase 2 to 3) begins. At the peak of isovolume contraction, LV
pressure exceeds aortic pressure and blood begins to eject from the LV into the aorta (Point 3). During this systolic ejection phase, LV volume decreases until
aortic pressure exceeds LV pressure and the aortic valve closes, which is known as the end-systolic pressure-volume point (ESPV) (Point 4). Stroke volume
(SV) is represented by the width of the PV loop as the volume difference between end-systolic and end-diastolic volumes (Points 1 and 2). The shaded area
within the loop represents stroke work. Load-independent LV contractility, also known as Emax, is deﬁned as the maximal slope of the ESPV point under
various loading conditions, known as the ESPV relationship (ESPVR). Effective arterial elastance (Ea) is a component of LV after- load and is deﬁned as the
ratio of end-systolic pressure and stroke volume. Under steady state conditions, optimal LV pump efﬁciency occurs when the ratio of Ea:Emax approaches 1.
(B) Representative PV loop in AMI (blue loop). LV contractility (Emax) is reduced; LV pressure, SV, and LV stroke work may be unchanged or reduced; and
LVEDP is increased. (C) Representative PV loop in cardiogenic shock (gray loop). Emax is severely reduced; LVEDV and LVEDP are increased; and SV is reduced.

and peripheral arterial disease (11–18). Lesion-speciﬁc

unloading and hemodynamic effects of MCS, which may

variables encompass anatomic characteristics such as

serve to reduce myocardial oxygen consumption and

left main stenosis, bifurcation disease, saphenous vein

ischemia, and improve coronary perfusion through effects

grafts, ostial stenoses, heavily calciﬁed lesions, and

on coronary blood ﬂow. Due to the presence of active and

chronic total occlusions (19–23). Lesions that supply a

ongoing myocardial ischemia, NSTEMI and STEMI are

large territory (including a last patent conduit, left

among the high-risk clinical scenarios for PCI. Several

main disease, or critical 3-vessel disease) also increase

factors make these patients high risk. Due to myocardial

risk should dissection or occlusion occur during PCI—

ischemia, left ventricular (LV) diastolic and systolic

particularly in combination with poor ventricular func-

function is impaired and contributes to elevated in- tra-

tion. Finally, the clinical setting, such as acute coronary

cardiac ﬁlling pressures. Furthermore, PCI is associated

syndrome or cardiogenic shock, can increase the risk of

with the risk of thrombotic embolization and infarct

an adverse event with PCI. The combination of severe

extension, which can lead to hemodynamic decompen-

left ventricular dysfunction, particularly ADHF, with a

sation. Finally, although standard therapy for STEMI is

lesion(s) that is difﬁcult to treat is an example of HR-PCI.

rapid myocardial reperfusion, up to one-third of STEMI

Need for an MCS device for HR-PCI depends upon

patients do not experience effective reperfusion as

the hemodynamic condition of the patient at the time of

assessed by resolution of ST-segment elevation, and

PCI, the anticipated risk of hemodynamic compromise

reperfusion itself may cause myocardial damage (reper-

during the procedure, and the need for hemodynamic

fusion injury) and life- threatening ventricular arrhyth-

support after revascularization. Risk calculators specif-

mias (24). Whether MCS can reduce myocardial injury in

ically designed to assess the real-time need for MCS dur-

the setting of acute occlusion and subsequent reperfusion

ing PCI do not exist and require further investigation.

for myocardial infarction is unknown.

Acute Myocardial Infarction

Advanced Heart Failure and Cardiogenic Shock

Although the vast majority of non-ST- and ST-segment

Heart failure is a major cause of morbidity and mortality

elevation myocardial infarction (NSTEMI and STEMI) pa-

worldwide. In the United States alone, an estimated 5.7

tients can be safely and effectively treated using standard

million adults 20 years or older have heart failure, of

techniques, selected patients may beneﬁt from the

whom nearly 50% have reduced LV ejection fraction (25).
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F I G U R E 2 Cardiac Effects of Mechanical Support

Illustrations of PV loops after activation of device therapy (gray loops). (A) Intra-aortic balloon pump (IABP) counterpulsation reduces both peak LV systolic
and diastolic pressures and increases LV stroke volume. The net effect is a reduced slope of arterial elastance (Ea2), (B) Percutaneous LV assist devices
(pLVAD: Impella and TandemHeart) signiﬁcantly reduce LV pressures, LV volumes, and LV stroke volume. The net effect is a signiﬁcant reduction in cardiac
workload. (C) Veno-arterial extra-corporeal membrane oxygenation (VA-ECMO) without a LV venting strategy increases LV systolic and diastolic pressure, while
reducing LV stroke volume. The net effect is an increase in arterial elastance (Ea).

Cardiogenic shock is deﬁned as systemic tissue hypo-

patients, who either have acutely decompensated or are

perfusion secondary to inadequate cardiac output despite

failing

adequate circulatory volume and LV ﬁlling pressure.

respectively (30). Both INTERMACS 1 and 2 patients may

Diagnostic hemodynamic criteria include: a systolic blood

be considered for temporary MCS support as a bridge to

pressure <90 mm Hg for >30 min; a drop in mean arterial

recovery, surgical MCS, or cardiac transplantation.

to respond to

aggressive

inotrope

therapy,

blood pressure >30 mm Hg below baseline, with a cardiac
index (CI) <1.8 L/min/m2 without hemodynamic support

Emerging Populations

or <2.2 L/min/m 2 with support; and a pulmonary capillary

Given the growing numbers of patients with compromised

wedge pressure (PCWP) >15 mm Hg (26–28).

cardiac function undergoing percutaneous coronary and

Among patients with advanced heart failure, techno-

valve therapies new applications for this technology are

logic advances have facilitated the use of surgically

emerging. In the adult population, patients with severe,

implanted left ventricular assist devices (LVADs) as a

nonoperable valve disease represent a rapidly growing

bridge to recovery, bridge to transplant, or for use as

population; carefully selected patients may beneﬁt from

permanent (destination) therapy (29). Biventricular assist

cardiac support during percutaneous aortic valvuloplasty

devices and the total artiﬁcial heart are also available as a

or aortic valve replacement (31,32). Similarly, patients

bridge to transplant for patients with biventricular heart

referred for electrophysiologic procedures with severe

failure. As a result, the use of MCS devices as a treatment

underling LV dysfunction may not tolerate sustained ar-

strategy for patients presenting with advanced heart

rhythmias during prolonged electrophysiological map-

failure or cardiogenic shock may be considered. The

ping and ablation procedures (33,34). Finally, patients

primary goal of such a strategy is stabilizing a critically

with right ventricular (RV) failure are at considerably

ill patient before making a decision regarding durable

higher risk for morbidity and mortality when presenting

therapy. Moreover, MCSs may allow for myocardial

with AMI, ADHF, or CS. Use of MCS for RV or biventricular

recovery, possibly obviating the need for destination

support has been reported (35–37) and represents an

therapy.

important new use for this technology. Although not yet

The optimal timing of MCS insertion in ADHF and
cardiogenic shock remains unknown and signiﬁcant

available in the United States, a dedicated RV support
device is under clinical evaluation (35,38).

practice variability exists. For patients with advanced HF,

Many children have or will develop disorders involving

the Interagency Registry for Mechanically Assisted Cir-

the myocardium. The current therapeutic options for

culatory Support (INTERMACS) has deﬁned seven clinical

circulatory support in the pediatric population are quite

proﬁles before implantation of a surgical VAD. Cardio-

limited. Primary indications for circulatory support in

genic shock is identiﬁed by INTERMACS proﬁles 1 and 2

pediatrics include heart failure related to congenital heart
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disease, cardiomyopathy and myocarditis, and cardiac

Hemodynamic Effects

allograft failure. The most commonly used method of

The IABP increases diastolic blood pressure, decreases

circulatory support in children is ECMO. According to the

afterload, decreases myocardial oxygen consumption,

most recent Extracorporeal Life Support Organization

increases coronary artery perfusion, and modestly en-

(ELSO) Registry Report from January 2013, a total of 6,225

hances cardiac output. The IABP provides modest ven-

pediatric patients (>31 days to 18 years) have been sup-

tricular unloading but does increase mean arterial

ported on ECMO since 1990 due to cardiac failure with a

pressure and coronary blood ﬂow. Patients must have

65% survival from ECMO but only a 49% survival to

some level of left ventricular function and electrical sta-

discharge (39). ECMO is able to provide complete circu-

bility for an IABP to be effective, as any increase in cardiac

latory support in a wide range of patients from newborns

output is dependent on the work of the heart itself.

to adults both with and without congenital heart disease

Optimal hemodynamic effect from the IABP is dependent

but is highly invasive and survival rates remain low at

on several factors, including the balloon’s position in the

40 to 50% (39). At this time, the only percutaneous device

aorta, the blood displacement volume, the balloon diam-

approved in the United States for short-term cardiac

eter in relation to aortic diameter, the timing of balloon

support in children is the IABP, with all other modalities

inﬂation in diastole and deﬂation in systole, and the

requiring surgical implantation. MCSs have been utilized

patient’s own heart rate, blood pressure and vascular

for circulatory support in older children successfully in

resistance (44).

their current conﬁguration (40,41). An important limitation in this patient population is femoral vessel size.
Further device iterations may allow broader application.

Contraindications and Complications
Aortic valve regurgitation of greater than a mild degree
has traditionally been considered a contraindication to

AVAILABLE DEVICES AND/OR STRATEGIES

the IABP as diastolic balloon inﬂation may worsen the
degree of regurgitation. Severe peripheral arterial or

Intra-Aortic Balloon Pump

aortic disease increases the risk of vascular complications

The IABP remains the most commonly used form of cir-

such as thromboembolism to the lower extremities or

culatory support. The IABP has two major components, a

visceral arteries (45).

balloon catheter and a pump console to control the

The majority of complications from IABP use are

balloon. The catheter itself is a double-lumen 7.5–8.0 Fr

vascular and may include stroke (46), limb ischemia,

catheter with a polyethylene balloon attached at its distal

or vascular trauma. Thrombocytopenia from platelet

end. One lumen is attached to the pump and is used to

deposition on the IABP membrane (or use of heparin),

inﬂate the balloon with gas. Helium is used because its

infection, and complications of immobility can occur in

low viscosity facilitates rapid transfer in and out of the

patients who remain on prolonged IABP therapy. Trauma

balloon, and because it absorbs very rapidly in blood in

to the aorta or ostia of visceral arteries, including

the case of balloon rupture. The second lumen of the IABP

the renal arteries, can occur and result in severe life-

is used for guidewire insertion and to transduce aortic

threatening complications such as bowel ischemia,

pressure.

atheroembolism, and acute kidney injury.

Timing of balloon inﬂation and deﬂation is based on

There is variability in use of anticoagulation for IABP.

electrocardiogram (ECG) or pressure triggers. The balloon

Many centers do routinely use anticoagulation, but others

inﬂates with the onset of diastole, which roughly corre-

do not, particularly with 1:1 pumping. No deﬁnitive

sponds with electrophysiologic repolarization or the

data exist to provide guidance. Each institution should

middle of the T-wave on the surface ECG. Following

establish its protocol, with monitoring of bleeding and

diastole, the balloon rapidly deﬂates at the onset of LV

ischemic complications.

systole, which is timed to the peak of the R-wave on the
surface ECG. Poor ECG quality, electrical interference, and

Left Atrial to Aorta Assist Devices

cardiac arrhythmias can result in erratic balloon inﬂation/

Currently, only one left atrial—aorta assist device is

deﬂation and make pumping inadequate or impossible.

commercially available, TandemHeart. This is a percuta-

Excessive tachycardia also mitigates the usefulness for

neously inserted circulatory assist device that pumps

diastolic pressure augmentation, due to a reduction of the

blood extracorporeally from the left atrium (LA) to the

time spent in diastole. Modern timing algorithms utilizing

iliofemoral arterial system via a transseptally placed

ﬁberoptics can somewhat improve device performance

left atrial cannula, thereby bypassing the LV (47). The

even in the setting of tachycardia or irregular pulse (42),

TandemHeart has four components: a 21-F transseptal

while larger volume balloons (i.e., 50 ml) have recently

cannula, a centrifugal pump, a femoral arterial cannula,

been developed (43).

and a control console. Regulatory status includes U.S.
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Food and Drug Administration (FDA) approval to provide

which is commonly present in elderly patients, may pre-

extracorporeal circulatory support for up to 6 h and CE

clude placement of the arterial cannula, or result in pe-

mark for use up to 30 days. It also has FDA approval to add

ripheral ischemia. In select cases with peripheral arterial

an oxygenator to the circuit allowing for concomitant LV

disease, a 5- or 6-F sheath can be placed antegrade into

unloading and oxygenation.

the superﬁcial femoral artery and spliced into the arterial

The transseptal cannula is made of wire-reinforced

outﬂow cannula to provide limb perfusion. Profound

polyurethane with a large end-hole and 14-side holes

coagulopathies and bleeding diatheses such as heparin

that allow for aspiration of left atrial blood. The arterial

induced thrombocytopenia or disseminated intravascular

perfusion cannula is available in sizes ranging from 15- to

coagulation are contraindications to use of TandemHeart

19-F and is the main determinant of maximal ﬂow. The

as are the presence of a right or left atrial thrombus.

centrifugal blood pump contains a hydrodynamic bearing

Anticoagulation is important to prevent thromboembo-

that supports a spinning impeller. The pump has a motor

lism or in situ thrombosis and few data with anticoagu-

chamber and a blood chamber that are separated by a

lants other than unfractionated heparin are available

polymeric membrane. The impeller is powered by a

although anecdotal reports exist. Activated clotting times

brushless DC electromagnetic motor, rotating between

about 300 are typically required. Alternative agents such

3,000 and 7,500 rpm. The external console controls

as bivalirudin or argatroban may be required in case of

the pump and provides battery backup in case of power

heparin contraindications and their use is empiric.

failure. A continuous infusion of heparinized saline

Complications from the device are similar to other

ﬂows into the lower chamber of the pump, which pro-

percutaneous support devices and include vascular

vides lubrication and cooling, and prevents thrombus

trauma and limb ischemia (47). Expertise with trans-

formation.

septal puncture is required, particularly given the caliber
of the venous cannula. The relatively low numbers of

Hemodynamic Effects

interventional cardiologists regularly performing trans-

During MCS with TandemHeart, both the LV and the

septal puncture in their practice is an important barrier

pump contribute ﬂow to the aorta simultaneously

to clinical application in many labs. Collaboration with

(thereby working in parallel, or tandem, rather than in

colleagues with transseptal experience and imaging

series). The redirection of blood from the LA reduces LV

guidance using intracardiac or transesophageal echocar-

preload, LV workload, ﬁlling pressures, wall stress, and

diography can facilitate training and safety of the trans-

myocardial oxygen demand (47,48). The increase in

septal puncture. Complications unique to transseptal

arterial blood pressure and cardiac output supports sys-

puncture, such as cardiac tamponade can occur; and these

temic perfusion. The 19-F arterial cannula allows up to

risks are increased among anticoagulated patients. Other

5 L/min of ﬂow whereas the 15-F cannula will allow up to

possible complications include thrombo-or air-embolism

3.5 L/min. These values are additive to left ventricular

and hemolysis. Care must be taken to prevent dislodge-

output through the aortic valve, although the contribu-

ment of the left atrial cannula, particularly during patient

tion of the heart is typically reduced as MCS support is

transport, or if the patient moves their leg, as dislodge-

increased due to changes in LV loading conditions (i.e.,

ment into the right atrium will result in massive right to

decrease in preload and increase in afterload). Coronary

left shunt and severe systemic desaturation. The cannula

ﬂow is driven by the perfusion pressure (diastolic pres-

may also migrate into a pulmonary vein leading to device

sure—right atrial pressure). With two pumps in parallel,

malfunction.

the aorta is perfused and pressured by both LV and the
TandemHeart, with the relative contribution of each

LV to Aorta-Assist Devices

varying and dependent upon LV response to the pump.

The Impella is a nonpulsatile axial ﬂow Archimedes-screw

Not infrequently LV contraction virtually ceases and

pump designed to propel blood from the LV into the

perfusion is pump-dependent with a ﬂat mean arterial

ascending aorta, in series with the LV (47). Three versions

pressure curve. Ventricular tachycardia or ﬁbrillation

are now available. The 12-F (Impella 2.5) and 21-F (Impella

usually but not always renders LVADs ineffective due to

5.0) devices which provide maximal ﬂow rates of 2.5 and

right ventricular failure (RVF) (49).

5.0 L/min, respectively, and a new 14-F device (Impella
CP) with an intermediate level of support of 3.0 to 4.0 L/

Contraindications and Complications

min. These devices are designed to be placed via the

Adequate RV function or a concomitant RVAD is usually

femoral artery, either percutaneously (2.5 and CP) or with

necessary to maintain left atrial volume. There is limited

a surgical cutdown (5.0). Alternate access sites such as the

experience with the use of the TandemHeart device in the

subclavian artery have been described but are not

setting of a ventricular septal defect or severe aortic

routinely used. The tip of the catheter is a ﬂexible pigtail

regurgitation (50,51). Severe peripheral arterial disease,

loop that stabilizes the device in the LV with a low
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likelihood of perforation. The pigtail connects to a 12-F

Impella may worsen right-to-left shunting and hypoxemia

(2.5 device), 14-F (CP device), or 21-F cannula (5.0 device)

in patients with a preexisting ventricular septal defect.

that contains the pump inlet and outlet areas, motor

The most commonly reported complications of Im-

housing, and pump pressure monitor. Due to its size, the

pella placement are limb ischemia, vascular injury, and

Impella 5.0 requires a surgical cutdown for deployment

bleeding requiring blood transfusion (55). Vascular com-

via the axillary or femoral artery. A possible advantage

plications common to all transfemoral procedures such

of the axillary approach is the potential for long-term

as hematoma, pseudoaneurysm, and arterial- venous ﬁs-

support (52).

tula, and retroperitoneal hemorrhage can occur with any

The proximal 9-F catheter shaft houses the motor

mechanical support device.

power leads and purge and pressure measurement lu-

Hemolysis due to mechanical erythrocyte shearing has

mens. The catheter’s proximal end consists of a hub

been reported within the ﬁrst 24 h of use in 5% to 10% of

for attachment of a console cable and side arms for

patients, and may respond to repositioning the device

attachment of purge solution and pressure-measurement

(55). Persistent hemolysis associated with acute kidney

tubing. As the Impella CP device has just recently become

injury is an indication for device removal.

available in the United States, the greatest experience to
date has been with the Impella 2.5 device.

Extracorporeal Membrane Oxygenation

Unlike the IABP, and comparable to the TandemHeart,

ECMO provides cardiopulmonary support for patients

the Impella does not require timing, nor is a trigger from

whose heart and lungs can no longer provide adequate

an electrocardiographic rhythm or arterial pressure

physiologic support. ECMO can be either veno-veno

needed. Similar to the TandemHeart, the device allows for

(V-V) for oxygenation only or veno-arterial (V-A) for

stability despite transient arrhythmias, but asystole and

oxygenation and circulatory support. In cases of biven-

ventricular ﬁbrillation are poorly tolerated. The device

tricular failure, V-A ECMO is the MCS of choice for

has received FDA approval for providing up to 6 h of

patients in cardiogenic shock and impaired oxygenation,

partial circulatory support whereas in Europe, the Impella

as it provides full cardiopulmonary support. ECMO

2.5 is approved for use of up to 5 days.

may be placed at the bedside without ﬂuoroscopic
guidance.

Hemodynamic Effects
The Impella pumps blood from the LV into the ascending
aorta, thereby unloading the LV and increasing forward
ﬂow. It reduces myocardial oxygen consumption, improves mean arterial pressure, and reduces pulmonary
capillary wedge pressure (53). The Impella 2.5 provides a
greater increase in cardiac output than the IABP but less
than the TandemHeart device. The more powerful Impella
CP and 5.0 devices are comparable to the TandemHeart
device in terms of support. Whether the Impella CP
further reduces native left ventricular stroke work and
wall stress at comparable ﬂow rates to the TandemHeart
based on device inﬂow location is unknown. Similar to the
TandemHeart, adequate RV function or concomitant
RVAD is necessary to maintain LV preload and hemodynamic support during biventricular failure or unstable
ventricular arrhythmias (49).

Similar to a cardiopulmonary bypass circuit used in
cardiac surgery, V-A ECMO involves a circuit composed of
a centrifugal, nonpulsatile pump for blood propulsion,
and a membrane oxygenator for gas exchange. A venous
cannula drains deoxygenated blood into a membrane
oxygenator for gas exchange, and oxygenated blood is
subsequently infused into the patient via an arterial
cannula. Anticoagulation is required and unfractionated
heparin is the most commonly used agent. The degree of
anticoagulation is dependent on the type of membrane
oxygenator used, with ACTs ranging between 180 and
250. Venous and arterial cannulae can vary in size but
typically will be similar to TandemHeart (20-F venous,
17-F arterial). An experienced cardiac perfusionist is
required for management of the ECMO system, whereas
they are not required for the other devices.
While any standard ECMO or perfusion system available in the hospital may be used, new portable ECMO
systems such as CardioHelp (Maquet) have now attained

Contraindications and Complications

FDA approval and may ﬁnd a useful role in catheterization

Use of the Impella is contraindicated in patients with a

laboratories due to the relative ease of implantation and

mechanical aortic valve or left ventricular thrombus.

initiation.

Aortic stenosis and regurgitation are relative contraindications, although reports of use in critical aortic stenosis

Hemodynamic Effects

for hemodynamic rescue or to facilitate valvuloplasty

V-V ECMO offers gas exchange without hemodynamic

exist (54). The device should not be placed in patients

support and is useful for conditions associated with

with severe peripheral arterial disease or who cannot

severe impairment of gas exchange with stable hemody-

tolerate systemic anticoagulation. Theoretically, use of

namics such as ARDS, or rarely, pulmonary embolism.
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On the other hand, V-A ECMO provides systemic circula-

generate continuous ﬂow with a minimal, low-amplitude

tory support with ﬂows sometimes exceeding 6 L/min

pulsatile component, may more closely approximate

depending on cannula sizes. However, due to high

native RV function.

myocardial oxygen demand (secondary to high ﬁlling

Right ventricular support using two venous cannulas

pressures and volume), V-A ECMO alone may not signiﬁ-

and ECMO or a TandemHeart centrifugal pump providing

cantly reduce ventricular wall stress (56). This has theo-

ﬂow from the right atrium to main pulmonary artery has

retic negative consequences on myocardial protection

been reported (69). Since the earliest reports, the Tan-

unless the LV is vented or unloaded by concomitant IABP

demHeart RV support device has been implanted for RVF

or Impella (57). Metabolic derangement and deleterious

in the setting of AMI (70,71), post-LVAD implant (72), se-

systemic effects of cardiogenic shock can often be cor-

vere pulmonary hypertension (73), and acute cardiac

rected within hours of initiation of ECMO.

allograft failure (74). Right internal jugular venous cannulation can be used and is particularly useful when the

Contraindications and Complications

distance from the femoral vein to the ﬁfth intercostal

Perfusionists familiar with device function and mainte-

space exceeds 58 cm or if femoral venous access is limited

nance should be readily available. Signiﬁcant aortic

by infection, thrombosis, or an inferior vena caval ﬁlter

insufﬁciency may worsen with ECMO and promote

(75). Close monitoring for antegrade cannula migration is

increased ventricular wall stress without a venting strat-

essential and may present as hypoxic respiratory failure,

egy. Patients with severe peripheral arterial disease

hemothorax, hemoptysis, decreased cardiac output, and

should not undergo peripheral cannulation and central

an acute decrease in device ﬂow. TandemHeart is not

Anticoagulation

FDA-approved for use as an RVAD (36). The Impella RP, a

is necessary to prevent thrombosis of the membrane

catheter-mounted axial ﬂow pump is undergoing evalu-

oxygenator and varies dependent upon type. Typical

ation for management of RVF (38). A potential advantage

activated clotting times (ACTs) are between 180 and 250.

of the Impella RP device is the need for only a single

Each laboratory and hospital with a mechanical support

venous access site. As experience with percutaneous RV

program should have target ACTs and regular monitoring

support devices grows, their role in the interventional

as part of its protocol. Alternative antithrombin agents

armamentarium of mechanical therapies for heart failure

may be required if contraindications to unfractionated

will evolve and will require algorithms for risk stratiﬁca-

heparin exist (58).

tion, patient and device monitoring, and weaning

cannulation

should

be

considered.

Complications of ECMO relate to bleeding and throm-

protocols.

boembolic events, as well as hemolysis. Thromboembolic
events may occur both in the circuit or the patient

Theoretical Comparison of

if adequate anticoagulation is not achieved. Cannulation

Hemodynamic and Myocardial Effects

complications, common to all large cannulae, may in-

The primary mechanism of beneﬁt of MCS is to reduce

clude venous thrombosis or distal arterial ischemia.

native LV stroke work and myocardial oxygen demand

Similar to TandemHeart, a second, antegrade, arterial

while maintaining systemic and coronary perfusion.

sheath inserted into the superﬁcial femoral artery can

Myocardial effects of reducing LV volume and pressure,

provide antegrade limb perfusion when needed. Stroke,

known as “LV unloading” have been well described (76).

either embolic or hemorrhagic, can occur and care

Device options can be classiﬁed according to pump type

must be taken to assure adequate but not excessive

and include: volume-displacement pumps (IABP) and

anticoagulation.

continuous-ﬂow pumps, which can be further grouped as
axial-ﬂow (Impella) or centrifugal-ﬂow (TandemHeart;

Right-Sided Support

CentriMag; Rotaﬂow) MCSs.

RVF is associated with increased morbidity and mortality

By displacing blood volume in the descending aorta

(59–67). Management of RVF focuses on reversing

during systole, the IABP generates a vacuum that is

the underlying cause, maintaining adequate preload,

replaced by blood from the LV. The net result is reduced

reducing RV afterload, and enhancing RV contractility. In

LV afterload, increased stroke volume, and a small

RVF refractory to medical therapy, options include sur-

reduction in LV stroke work (77). However, the IABP is

gical RVAD implantation, veno-arterial ECMO, cardiac

functionally limited by balloon capacity, accurate timing,

transplantation, or a total artiﬁcial heart (67). Historically,

and a dependence on native LV function. Whether newer

percutaneous mechanical support for RVF has been

generation, larger capacity IABPs will provide more car-

limited to the IABP, which only indirectly beneﬁts RV

diac support remains unknown.

function by reducing LV afterload and enhancing coro-

With minimal native LV function continuous ﬂow de-

nary perfusion. Since RV stroke work requires one-sixth

vices actively reduce LV stroke work and myocardial ox-

the energy expenditure of the LV (68), pumps that

ygen demand, and can maintain systemic perfusion.
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Output of these devices is determined by rotor speed and

randomized, controlled trials have failed to demonstrate

is inﬂuenced by preload and afterload. Whether axial or

conclusive proof of IABP beneﬁt. The IABP-SHOCK II Trial

centrifugal ﬂow pumps have different effects on LV

(84) randomized 600 patients with cardiogenic shock

unloading has not been clearly established (78,79). Dif-

complicating AMI to IABP or no IABP, with all patients

ferences between these two device types that impact

expected to undergo early revascularization and to

hemodynamic effects are the rotor sizes and the caliber of

receive optimal medical therapy. The vast majority (83%)

the inﬂow and outﬂow segments.

of IABP were inserted after the primary PCI procedure; at

Technical differences between axial and centrifugal

30 days, there were 119 deaths (39.7%) in the IABP group

devices exist and relate to the location of device inﬂow

and 123 deaths (41.3%) in the control group (p ¼ 0.69), and

and outﬂow. The Impella is placed across the aortic valve

no signiﬁcant differences in secondary clinical, labora-

into the LV for direct unloading, while the TandemHeart

tory, and resource utilization endpoints. Rates of major

inﬂow cannula is placed across the interatrial septum into

bleeding, sepsis, and stroke were also similar between the

the LA, thereby reducing LV stroke work indirectly by

two groups (84).

reducing LV preload. No patient-level data exist currently

Despite limited evidence of meaningful beneﬁt, IABP

to suggest that any meaningful difference is observed

has received a Class IIa indication for use during STEMI

between unloading via the LA or the LV. In contrast,

complicated by cardiogenic shock in the 2013 ACCF/AHA

ECMO, which displaces venous volume into the arterial

guideline statement pertaining to STEMI management

circulation, can signiﬁcantly increase after-load on the

(81). IABP use in STEMI without shock was not addressed

LV, thereby potentially reducing LV stroke volume,

except to note that it may be useful for mechanical com-

increasing myocardial oxygen demand, and necessitating

plications of STEMI. Additionally, the current ACCF/AHA

“venting” of the LV (80). The major technical difference

guideline statement (5) and the most recent SCAI expert

is that to achieve device ﬂow rates of 5 L/min, the

consensus document (85) on PCI without on-site cardiac

TandemHeart device requires venous and arterial can-

surgery agree that the ability to provide IABP support

nulation with trans-septal puncture, while the Impella

during transport of unstable patients is a requirement

5.0 pump requires surgical vascular access.

for such centers.

CLINICAL DATA AND GUIDELINES

Size Pre-PCI Acute Myocardial Infarction) trial was a

The CRISP AMI (Counterpulsation to Reduce Infarct
30-center randomized controlled trial that investigated
The American College of Cardiology, the American

whether routine IABP placement immediately before

Heart Association, and the Society for Cardiovascular

reperfusion reduced myocardial infarct size in patients

Angiography and Intervention have published expert

presenting with an anterior STEMI. The trial enrolled

consensus documents and clinical practice guidelines

337 patients in nine countries. No reduction in infarct

referencing the use of left ventricular assist devices. The

size as assessed by cardiac magnetic resonance imaging

most recent guidelines relating to percutaneous coronary

was found 3 to 5 days following coronary intervention,

intervention and management of acute coronary syn-

and no signiﬁcant difference in survival was observed at

dromes recommend consideration of hemodynamic sup-

6-month follow-up between groups (86).

port devices in the settings of HR-PCI and STEMI with

In a large study from the National Cardiovascular

cardiogenic shock and for use in unstable patients being

Data Registry, IABP was used in only 10.5% of 181,599

transported from one hospital center to another (5,81).

high-risk interventions (deﬁned unprotected left main
intervention, reduced left ventricular ejection fraction,

Intra-Aortic Balloon Pump

STEMI and cardiogenic shock) (83). IABP use in this

In a retrospective study of 48 patients who underwent

analysis was not associated with lower mortality and

primary PCI for acute myocardial infarction complicated

varied widely between centers. Since all retrospective

by cardiogenic shock, those that had an IABP placed

nonrandomized studies are subject to signiﬁcant selec-

before PCI had a lower peak creatine kinase (CK), lower

tion and referral bias it remains unknown what the

in-hospital mortality and fewer major adverse cardiac

outcomes of the 18,990 patients would have been had

events than those with IABP inserted after PCI (82).

an IABP not been used.

However, a nonrandomized study examined the use of

Finally, a prospective randomized clinical trial, BCIS-1,

IABP in HR-PCI using the National Cardiovascular Data

enrolled 301 patients across 17 centers in the UK and

Registry database and found no differences in overall

failed to show a mortality beneﬁt of routine IABP

mortality and wide regional variation in the use of IABP

over provisional IABP use among those referred for

in this setting (83). Similarly, a meta-analysis of IABP use

HR-PCI (87). On the other hand, routine IABP use signiﬁ-

in AMI found no beneﬁt and potential harm, including

cantly reduced major procedural complications (1.3% vs.

a

10.7%, p < 0.001), particularly procedural hypotension.

higher

risk

of

stroke

(46).

Finally,

prospective
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Procedural hypotension in the group randomized to no

high with a 90% success rate with multi-vessel revascu-

IABP necessitated crossing over to IABP in 12% of pa-

larization and 8% rate of 30-day major adverse cardiac

tients. A long-term follow-up analysis of BCIS-1 out to 51

events. Survival was 91% and 88% at 6 and 12 months,

months showed a 34% relative reduction in all-cause

respectively.

mortality with routine IABP use in patients with severe
ischemic cardiomyopathy undergoing HR-PCI (88).

The PROTECT 2 trial is the largest single randomized
clinical trial of HR-PCI using MCS ever performed and
enrolled 452 symptomatic patients with complex three-

Percutaneous Mechanical Circulatory Support

vessel disease or unprotected left main coronary artery

The opportunity for these systems to provide greater

disease and severely depressed left ventricular function

hemodynamic support than IABP has been demonstrated

to IABP (n ¼ 226) or Impella 2.5 (n ¼ 226) support for HR

(89); however, there have been few randomized clinical

PCI (95). The primary end point was a 30-day composite

trials. In an analysis of 117 patients with severe cardio-

of 11 adverse events and was not signiﬁcantly different

genic shock refractory to IABP and/or vasopressor

between groups (Impella 35.1% vs. 40.1% IABP, p ¼ 0.227)

therapy, Kar et al. (89) observed signiﬁcant improvements

in the intent-to-treat population. The trial was stopped

in cardiac index, systolic blood pressure, and urine

early for futility. Primary endpoint differences were

output with TandemHeart support over an average

greater in the per protocol population (34.3% Impella vs.

implant time of 6 days. In addition, pulmonary capillary

42.2% IABP, p ¼ 0.092). Impella provided superior he-

wedge pressure and serum creatinine levels decreased.

modynamic support in comparison with IABP, and at

Despite these clinical and laboratory improvements,

90 days a trend toward decreased events was observed in

30-day mortality remained high at 40% with signiﬁcant

the intent-to-treat population (40.6% Impella vs. 49.3%

bleeding complications. Whether observed mortality

IABP, p ¼ 0.066). Differences were magniﬁed in the per

would have been higher without circulatory support

protocol population (40.0% Impella vs. 51.0% IABP, p ¼

cannot be determined; however, it bears emphasis that

0.023) (90). A subsequent analysis redeﬁning myocardial

these were the sickest subgroup with true refractory

infarction as the development of new Q waves or CKMB

shock with almost one-half undergoing CPR during their

more than eight times the upper limit of normal demon-

course. In a small open-labeled study, Burkhoff et al. (90)

strated lower rates of events in patients treated with

randomized 33 patients within 24 h of developing

Impella (composite event rate 37% vs. 49%, p ¼ 0.014),

cardiogenic shock to treatment with an IABP or Tandem-

respectively; and major adverse cardiac and cerebrovas-

Heart. Compared with IABP, the TandemHeart device

cular events 22% vs. 31%, p ¼ 0.034) (96). Interestingly,

resulted in a greater increase in cardiac index and

this is consistent with the late mortality reduction

decrease in pulmonary capillary wedge pressure, but no

demonstrated in BCIS-1 and has been the cause of intense

difference in severe adverse events or 30-day mortality.

speculation. The potential mechanism for late beneﬁt

Low statistical power due to small numbers precluded

may relate to more stable procedural hemodynamics

deﬁnitive conclusions.

allowing for greater and more complete revascularization,

Similar hemodynamic improvements have been demonstrated with the Impella 2.5 system in CS. Seyfarth

including allowing for more complex PCI procedures such
as rotational atherectomy (97).

et al. (91) randomly allocated 25 patients with AMI and

No comparable randomized trial of HR-PCI with the

cardiogenic shock to receive percutaneous support with

TandemHeart device exists. Alli et al. (98) reported a se-

an IABP or Impella 2.5 device. Early increases in cardiac

ries of 54 patients using the TandemHeart for HR-PCI. All

index were greater with Impella (þ0.49 L/(min m2 )

patients were deemed high risk for surgery and under-

vs. þ0.11 L/min/m2 ; p ¼ 0.02). Similar to the TandemHeart

went complex PCI, with left main and multivessel stent-

data, 30-day mortality was high 46%) and not different

ing performed in 64%. Procedural success was high at

between the two groups. Elective use of the Impella 2.5

97%, and 6-month survival was 87%. Besides demon-

system has been demonstrated to be safe in HR-PCI (92)

strating the safety and feasibility of this device to allow

although an earlier study raised some concerns about

complex intervention in a very high-risk, non-surgical

hemolysis and increased left ventricular volume after

group, hemodynamics improved during support, with a

device activation (93).

decrease in cardiac ﬁlling pressures and increase in

A large observational study of the Impella 2.5 device in

cardiac output. No patient required hemodialysis but

HR-PCI has been published (94). Most patients were

vascular complications occurred in 13%. Other small

extremely high risk, including inoperable patients with a

series of patients undergoing HR-PCI with TandemHeart

high prevalence of chronic kidney disease, prior coronary

support have also been reported (99,100).

artery bypass grafting, and severe LV dysfunction, as

It is important to note that the sickest patients with

well as a high prevalence of NYHA class III to IV heart

most signiﬁcant hemodynamic compromise are clearly

failure. Despite these risk factors, procedural success was

not readily enrolled in large clinical trials. Clinical
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operators frequently empirically use commercially avail-

Timing of MCS insertion depends on the indication for

able MCS for hemodynamic support. Exclusion from

use. For cardiogenic shock, a support device should be

enrollment of those candidates who would have been the

inserted as soon as possible, particularly if initial attempts

most likely to beneﬁt from enhanced MCS will decrease

with ﬂuid resuscitation and pharmacologic support fail

the power of clinical trials to detect outcome differences.

to show any signiﬁcant hemodynamic beneﬁt, and before
PCI (110). Early initiation of MCS support can mitigate

Extra-Corporeal Membrane Oxygenation (ECMO)

the consequences of systemic hypoperfusion, worsening

ECMO is part of a broader category termed extracorporeal

ischemia, and declining cardiac function. Hemodynamic

life support (ECLS) (101). This term includes cardiopul-

evaluation and monitoring with right heart catheteriza-

monary support, extracorporeal CO 2 removal, and ECMO.

tion is helpful in most cases.

A common cardiac indication for ECMO is in patients

For prophylactic support during elective, high-risk

with postcardiotomy syndrome and an inability to wean

procedures, the device should be placed before the start

from cardiopulmonary bypass. ECMO has also been

of the intervention. If a patient is hemodynamically

used to support patients with allograft failure following

stable post-procedure, the device can usually be removed

cardiac transplantation, fulminant myocarditis, and se-

immediately. Patients who remain hemodynamically un-

vere decompensated heart failure refractory to standard

stable post-procedure or those with cardiogenic shock

therapies. As a bridge to deﬁnitive therapy, ECMO has

may remain on percutaneous support until their hemo-

also been used in patients with cardiogenic shock from

dynamic status improves. Although these devices are

acute coronary syndromes and as a bridge to transplant

labeled for as little as 6 h of use, they have been suc-

with or without the use of other ventricular assist devices.

cessfully employed for days or even weeks in selected

Multiple reports of ECMO being instituted for cardiac ar-

cases of prolonged shock. A team approach with in-

rest (102,103) exist, and the institution of ECMO for car-

put from advanced heart failure specialists and VAD/

diovascular collapse and cardiac arrest is rapidly growing

transplant surgeons can facilitate decision making.

in popularity (104). A major advantage is the relative ease
of implementation, but a disadvantage is the need for

MCS Device Selection

specialized perfusion expertise and nursing. Nichol et al.

Multiple factors must be considered when choosing MCS

reviewed 84 studies of ECMO instituted for cardiogenic

including: the hemodynamic condition of the patient,

shock or cardiac arrest and showed an overall survival

hemodynamic impact of the device, technical consider-

of 50% (105).

ations including ease and rapidity of insertion, and the

Analysis of the ELSO (Extracorporeal Life Support Or-

ultimate goals of support. In emergent situations (e.g.

ganization) registry for ECMO used in the setting of adult

STEMI), IABP is often selected as the quickest and most

cardiac arrest demonstrated a 27% survival to hospital

familiar way to obtain some degree of hemodynamic

discharge with the need for renal replacement therapy

stabilization, especially in the setting of AMI with pump

increasing odds of mortality (106). A more recent experi-

failure. The initial effects of the IABP on coronary blood

ence similarly found 49% survival with use of either MCS

ﬂow may be particularly desirable in this setting as well.

or ECMO in cardiogenic shock, with ongoing cardiopul-

However, the IABP often requires concomitant pharma-

monary resuscitation a risk factor for increased mortality

cologic support to maintain hemodynamics in those with

(107). There are no large randomized controlled trials with

pump failure, and recent data raise questions about the

use of ECMO.

efﬁcacy and safety of IABP support in this setting
(46,86,111,112). Operators familiar with the Impella may

RECOMMENDATIONS FOR USE

elect to insert this device instead in such patients, in order to minimize or obviate pressor use, reduce myocardial

When to Consider Mechanical Circulatory Support

oxygen demand and improve systemic perfusion, thereby

For historic reasons, positive inotropes and vasopressors

avoiding systemic shock. In experienced centers, inser-

have been ﬁrst-line therapy for hemodynamic instability

tion of an Impella 2.5 or CP device may be as rapid as an

and cardiogenic shock. Given the lack of data showing

IABP.

beneﬁt with these agents, and the potential for harm with

If hemodynamic compromise occurs despite appropriate

coronary and peripheral vasoconstriction, MCS may be

medical management and/or IABP, one may consider more

considered in carefully selected patients with severe he-

powerful hemodynamic support devices such as an axial or

modynamically unstable cardiovascular presentations.

centrifugal ﬂow pump. Use of these devices requires an

Table 1 lists the most common scenarios in which MCS

experienced team and may not be possible under all cir-

may be used to provide hemodynamic support and bridge

cumstances, particularly with adverse conditions. With

to recovery or deﬁnitive therapy. Table 2 provides a guide

experience the Impella 2.5 or CP can be inserted rapidly

for clinical use for HR PCI.

and provide a higher magnitude of support compared to
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TABLE 1

Suggested Indications for Percutaneous MCS

Indication

Comments

Complications of AMI

Ischemic mitral regurgitation is particularly well-suited to these devices as the hemodynamic disturbance is usually
acute and substantial. Acutely depressed LV function from large AMI during and after primary PCI is an increasing
indication for temporary MCS use. Cardiogenic shock from RV infarction can be treated with percutaneous right
ventricular support.

Severe heart failure in the setting of
nonischemic cardiomyopathy

Examples include severe exacerbations of chronic systolic heart failure as well as acutely reversible cardiomyopathies
such as fulminant myocarditis, stress cardiomyopathy, or peripartum cardiomyopathy.
In patients presenting in INTERMACS proﬁles 1 or 2, MCS can be used as a bridge to destination VAD placement or
as a bridge to recovery if the ejection fraction rapidly improves (108).

Acute cardiac allograft failure

Primary allograft failure (adult or pediatric) may be due to acute cellular or antibody-mediated rejection, prolonged
ischemic time, or inadequate organ preservation.

Post-transplant RV failure

Acute RV failure has several potential causes, including recipient pulmonary hypertension, intraoperative injury/
ischemia, and excess volume/blood product resuscitation. MCS support provides time for the donor right ventricle
to recover function, often with the assistance of inotropic and pulmonary vasodilator therapy (109).

Patients slow to wean from cardiopulmonary
bypass following heart surgery

Although selected patients may be transitioned to a percutaneous system for additional weaning, this is rarely done.

Refractory arrhythmias

Patients can be treated with a percutaneous system that is somewhat independent of the cardiac rhythm. For recurrent,
refractory, ventricular arrhythmias, ECMO may be required for biventricular failure.

Prophylactic use for high risk PCI

Particularly in patients with severe LV dysfunction (EF <20% to 30%) and complex coronary artery disease involving a
large territory (sole-remaining vessel, left main or three vessel disease) (94,95,98).

High-risk or complex ablation of ventricular
tachycardia

Similar to HR-PCI, complex VT ablation can be made feasible with percutaneous support. MCS use allows the patient
to remain in VT longer during arrhythmia mapping without as much concern about systemic hypoperfusion.

High-risk percutaneous valve interventions

These evolving procedures may be aided with the use of MCSs.

an IABP. For patients who continue to deteriorate despite

or TandemHeart device should permit completion of a

such support, TandemHeart using the larger arterial

revascularization procedure without hypotension and

outﬂow cannula, ECMO, or surgical cutdown for delivery of

systemic hypoperfusion, reduce vasoconstriction more

an Impella 5.0 should be considered.

quickly, and achieve a greater likelihood of improved

Operators must consider the advantages and disadvantages of initially selecting a device to achieve higher

late survival. Such an approach is supported by recent
guidelines (5).

cardiac output by inserting it at the beginning of a highrisk procedure or at the early stages of ADHF or shock,

Gaps in Knowledge

and perhaps obviating peripheral and coronary vasocon-

Given the limited prospective, randomized, multicenter

striction that accompany vasopressor therapy. In patients

data with MCS use, these recommendations must be

with cardiogenic shock and mechanical complications,

tempered with understanding of knowledge gaps. The

the TandemHeart or Impella 5.0 offers the greatest car-

effects of percutaneous MCS on reducing LV stroke work

diac output and hemodynamic support while the indi-

and myocardial oxygen demand in acute myocardial

vidual is evaluated for surgery. Inotropes may still be

infarction are poorly understood. MCSs may reduce

required to support RV function after placement of a left-

infarct size and/or ischemic complications, but available

sided support device. Patients with biventricular failure

clinical data so far does not support this indication.

and/or impaired oxygenation may require ECMO support.

In patients undergoing HR-PCI, more data are needed

Biventricular support with two different devices (e.g.,

on subgroups of patients that may beneﬁt from support

TandemHeart for RV support and Impella or IABP for LV

(e.g., based on clinical or angiographic characteristics).

support) has also been reported.

Likewise, for patients with AMI complicated by cardio-

Early MCS implantation before the patient requires

genic shock, the limitations of IABP use are apparent.

multiple vasopressors is theoretically attractive but re-

A phase III, multicenter, three-arm study comparing

quires testing in controlled trials. Insertion of an Impella

outcomes with IABP, MCS or neither, with power to

TABLE 2

Suggested Schema for Support Device in High-Risk PCI

Patient With Left Main, Last Remaining
Conduit, or Severe Multivessel Disease
Normal or mildly reduced left ventricular function
Severe left ventricular dysfunction (EF <35%) or recent
decompensated heart failure

Anticipated
Noncomplex PCI
None
IABP/Impella
as back up

Anticipated Technically Challenging or Prolonged PCI
IABP/Impella as back up
Impella or TandemHeart, choice dependent upon vascular anatomy, local
expertise, and availability. ECMO for concomitant hypoxemia or RV failure.

A suggested schema for use of support devices for high-risk PCI based upon clinical and anatomic circumstances. The greater the likelihood of hemodynamic compromise or collapse the greater the
potential beneﬁt of MCS.
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determine clinical outcome differences not only in

IABP use (117,118). However, as described above, the

short-term hemodynamics but also long-term survival, is

CRISP-AMI study (101) found no difference in mean ﬁnal

needed. With the re-emergence of ECMO at many centers,

infarct size between STEMI patients (not complicated by

the trade-offs between complete cardiopulmonary sup-

cardiogenic shock) who received routine IABP compared

port versus complexity of intervention and monitoring

with those who did not. Animal studies of LV unloading

and potential for complications and impaired myocardial

with Impella appeared more favorable (56,119–121) and a

protection need to be deﬁned. On the other hand, partial

preliminary clinical report of Impella for infarct size

LV support may offer beneﬁts over current MCS tech-

reduction in the STEMI setting was encouraging (122). The

nology in terms of ease of application and patient

MINI-AMI (Minimizing Infarct Size with Impella 2.5

acceptability.

Following PCI for Acute Myocardial Infarction) trial

The potential advantages of these devices over phar-

sought to measure this beneﬁt, but this study was

macologic therapy such as inotropes, with known adverse

terminated before completion (123). The TandemHeart

effects on myocardial oxygen consumption and cardiac

device will be studied in a trial of similar design entitled

rhythm, need to be determined in controlled studies.

TRIS (TandemHeart To Reduce Infarct Size) (Howard C,

Finally, more development and clinical data are needed

personal communication). This trial will test the hypoth-

on RV support devices.

esis that left ventricular unloading before primary PCI will
reduce infarct size. No human subject studies of ECMO

Cost Effectiveness

have been announced to test efﬁcacy in myocardial

The support devices discussed in this document are

salvage but portable ECMO devices that have recently

expensive, with acquisition, disposable, and operating

become available may have an important role to play in

costs greatly exceeding that of the IABP. Costs incurred

the future.

during both the initial hospitalization and any subsequent
readmissions need to be considered. This is particularly

CONCLUSIONS AND SUMMARY

true as most patients are older, have multiple comorbidities, and may experience prolonged hospital length of

The availability of percutaneous MCS has broadened

stays and high readmission rates. A recent European

therapeutic options for patients that require hemody-

study modeled cost-effectiveness of an Impella in com-

namic support. A variety of devices are now available,

parison with IABP using decision trees bases upon rates of

each with speciﬁc technical and clinical nuances.

endpoints reported in the literature. The Impella was

Unfortunately, deﬁnitive clinical evidence is in many

associated with an incremental quality-adjusted life-year

cases either unavailable or controversial. We provide the

(QALY) between 0.22 (with Euro registry data) and

following consensus-based summary statements based

0.27 (with U.S. registry data). The incremental cost-

upon the anticipated hemodynamic effects and risks,

effectiveness ratio (ICER) of the device varied between

clinical outcomes data as well as knowledge gaps.

V38,069/$52,063 (with Euroregistry data) and V31,727/
$43,390 (with U.S. registry data) per QALY compared with

1. Percutaneous MCS provides superior hemodynamic

IABP, which is within conventionally accepted parame-

support compared to pharmacologic therapy. This is

ters of cost effectiveness (113).

particularly apparent for the Impella and Tandem-

A second study utilizing 2010–2011 MedPAR data
evaluated the cost-effectiveness of emergency MCS for

Heart devices. These devices should remain available clinically and be appropriately reimbursed.

cardiogenic shock (N ¼ 883) compared with surgical

2. Patients in cardiogenic shock represent an extremely

ECMO or VAD therapy (N ¼ 305). MCS was associated

high risk group in whom mortality has remained

with better survival to hospital discharge (56% vs. 42%,

high despite revascularization and pharmacologic

p < 0.001), reduced LOS (13.2 and 17.9 days, respectively,

therapies. Early placement of an appropriate MCS

p ¼ 0.055) and signiﬁcantly lower inpatient costs ($90,929

may be considered in those who fail to stabilize

and $144,257, respectively, p < 0.001) (114).

or show signs of improvement quickly after initial
interventions.

Future Directions: Myocyte Protection and Recovery

3. MCS may be considered for patients undergoing

Another potential use of ventricular support is myocyte

high-risk PCI, such as those requiring multivessel, left

preservation during acute ischemic insult (115). Ventric-

main, or last patent conduit interventions, particu-

ular unloading may reduce myocardial infarct size

larly if the patient is inoperable or has severely

through enhanced hemodynamics, preserved energetics,

decreased ejection fraction or elevated cardiac ﬁlling

and activation of cardioprotective mechanisms (48,116).

pressures.

Despite limited unloading potency, some animal infarct

4. In the setting of profound cardiogenic shock, IABP is

model studies found improved myocyte recovery with

less likely to provide beneﬁt than continuous ﬂow
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pumps including the Impella CP and TandemHeart.

8. MCSs may be used for failure to wean off cardiopul-

ECMO may also provide beneﬁt, particularly for

monary bypass, considered as an adjunct to high-risk

patients with impaired respiratory gas exchange.

electrophysiologic procedures when prolonged hy-

5. Patients with acute decompensated heart failure
may beneﬁt from early use of percutaneous MCS

potension is anticipated, or rarely, for valvular
interventions.

when they continue to deteriorate despite initial

9. Severe biventricular failure may require use of both

interventions. MCS may be considered if patients are

right- and left-sided percutaneous MCS or veno-

candidates for surgically implanted VADs or if rapid

arterial ECMO. Certain patients may respond to

recovery is expected (e.g., fulminant myocarditis or

LVAD implantation with inotropes and/or pulmonary

stress-induced cardiomyopathy).

vasodilators to support the right heart. MCS may also

6. When oxygenation remains impaired, adding an
oxygenator to a TandemHeart circuit or use of ECMO
should be considered based upon local availability.
7. There are insufﬁcient data to support or refute the
notion that routine use of MCSs as an adjunct to pri-

be considered for isolated acute RVF complicated by
cardiogenic shock.
10. Registries and randomized controlled trials comparing
different strategies in different clinical scenarios are
critically needed.

mary revascularization in the setting of large acute

11. Early analyses suggest cost-effectiveness of MCS for

myocardial infarction is useful in reducing reperfu-

emergent use in comparison to surgical ECMO or VAD

sion injury or infarct size. Exploratory studies are

support, and for elective use in comparison to IABP.

underway.

Further data are necessary.
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